Real-World Healthcare Resource Utilization (HCRU) and Costs Among Patients with Hematopoietic Stem Cell Transplant (HSCT) or Solid Organ Transplant (SOT) with Covid-19 in a Commercially Insured or Medicare Advantage (MA) Population

Document Type

Conference Proceeding

Publication Date

6-1-2023

Publication Title

Am J Transplant

Keywords

oxygen, conference abstract, coronavirus disease 2019, disease management, drug therapy, female, follow up, hematopoietic stem cell, hospitalization, human, incidence, intensive care unit, length of stay, major clinical study, male, medicare, retrospective study, special situation for pharmacovigilance, therapy

Abstract

Purpose: Estimate the incidence of COVID-19 and long COVID-19 syndrome and evaluate HCRU and costs associated with COVID-19 among HSCT and SOT patients. Methods: HSCT and SOT patients were retrospectively identified from the Health-Core Integrated Research Database between 4/1/2018 and 3/31/2022 (study end date). The first transplant date or 4/1/2020 was set as the index date, whichever came last. Patients were enrolled in a commercial or MA insurance plan for 1 year prior to index and followed until disenrollment, study end date or death. COVID-19 was identified through diagnosis codes on medical claims and outpatient laboratory results. Incidence rates (IRs) for COVID-19 and long COVID-19 were calculated. Hospitalized patients were classified as severe (intensive care unit stay with noninvasive high flow oxygen or invasive respiratory/cardiovascular support or discharge status of expired) or moderate (all other hospitalizations); length of stay (LOS) and inpatient costs were calculated. All-cause HCRU and costs were calculated for the 30 days pre/post-COVID-19. Results: In total, 28,698 HSCT or SOT patients were identified (mean age: 53 years; 58% male) and followed for 17 months on average. During follow up, 16% of HSCT/SOT patients developed COVID-19; the IRs of COVID-19 and long COVID-19 are shown (Figure). Total mean costs among these patients increased from $9,144 pre-COVID-19 to $30,181 post-COVID-19. Of the 33% of HSCT or SOT patients hospitalized for COVID-19, 46% were severe with a mean LOS of 20 days and total cost of $121,609, while 54% were moderate with a mean LOS of 11 days and total cost of $34,210. Conclusions: Patients with HSCT or SOT have high IRs of COVID-19 with substantial associated costs. These findings show high burden of COVID-19 and unmet need, highlighting opportunities to improve COVID-19 prevention and care for this population. CITATION INFORMATION: Pizzicato L., Willey V., Pollack M., Wenziger C., Glasser L., Teng C., Hirpara S., Dube C., Verduzco-Gutierrez M., Cunningham D. Real-World Healthcare Resource Utilization (HCRU) and Costs Among Patients with Hematopoietic Stem Cell Transplant (HSCT) or Solid Organ Transplant (SOT) with Covid-19 in a Commercially Insured or Medicare Advantage (MA) Population AJT, Volume 23, Issue 6, Supplement 1. DISCLOSURES: [Figure presented]

Medical Subject Headings

Infectious Diseases

PubMed ID

Not assigned.

Volume

23

Issue

6

First Page

S674

Find It @ Sladen

Share

COinS